ArticleScientific reports2026
A cross-sectional study on associated factors of Chinese herbal medicine use in middle-aged and older adults with dyslipidaemia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The efficacy of Chinese herbal medicine (CHM) in treating dyslipidaemia has been demonstrated. However, the prevalence of CHM treatment and factors influencing its use in middle-aged and older patients with dyslipidaemia in China remain unclear. We aimed to investigate the prevalence and contributing factors of CHM use among middle-aged and older Chinese patients with dyslipidaemia. The data analyzed in this study were extracted from the fourth wave (2018) of the China Health and Retirement Longitudinal Study (CHARLS). Information on demographic and socioeconomic characteristics, health service use, health status, and history of CHM use was obtained. A logistic regression model was used to identify the key factors (demographics, health service use, and health status) that predict CHM use in the treatment of dyslipidaemia. In this cross-sectional study, a total of 4341 participants (middle-aged adults, 56.46%; older adults, 42.36%; males, 45.06%; females, 54.94%) with dyslipidaemia were included, and the prevalence of CHM use for dyslipidaemia was 14.08%. A logistic regression analysis revealed that compared with participants who did not use CHM, those who used CHM were more likely to have no income (OR 1.33; 95% CI 1.02, 1.74), visit traditional Chinese medicine hospitals (OR 2.85; 95% CI 1.71, 4.74), engage in self-treatment (OR 1.70; 95% CI 1.35, 2.13), report fair or poor health status (fair, OR 1.60; 95% CI 1.13, 2.26; poor, OR 1.99; 95% CI 1.36, 2.86), and a higher modified Chinese multimorbidity-weighted index (OR 1.06; 95% CI 1.03, 1.10). In the joint effect analysis, patients who visited a Chinese medicine hospital and had a stroke were more likely to use CHM (OR 6.90; 95% CI 2.08, 22.88) than those who did not visit a Chinese medicine hospital and did not have a stroke. In this study, the prevalence of CHM use was 14.08% among middle-aged and older patients with dyslipidaemia and was correlated with demographic factors, multimorbidity, and health service preferences in China. These findings suggest the need to integrate patient-specific factors into CHM-based dyslipidaemia management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.